Inhibition of the renin-angiotensin system and target organ protection
- PMID: 19262496
- DOI: 10.1038/hr.2009.5
Inhibition of the renin-angiotensin system and target organ protection
Abstract
The renin-angiotensin system (RAS) is involved in the pathological mechanisms of target organ damage, as well as in the induction of hypertension. RAS inhibition by angiotensin converting enzyme (ACE) inhibitors and angiotensin (Ang) II receptor blockers can prevent tissue damage by inhibition of Ang II type 1 receptor signaling. A beneficial effect of RAS inhibition on the heart, vasculature and kidney in cardiovascular disease has been reported. However, RAS inhibition can also prevent fibroproliferative diseases and damage of other tissues, such as brain, adipose tissue and muscle, because local RAS has an important role in tissue damage compared with circulating RAS. Moreover, other players, such as Ang II type 2 receptor signaling, aldosterone and ACE2 have been highlighted. Furthermore, there has also been a focus on the emerging concept of regulation of RAS, such as receptor-interacting proteins and receptor modifications, in the new discovery of therapeutic agents for tissue protection. The RAS has a pivotal role in various target organ damage, with complicated mechanisms; therefore, blockade of RAS may be therapeutically effective in preventing organ damage, as well as in having an antihypertensive effect.
Similar articles
-
[Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].Rev Prat. 2004 Jun 15;54(11):1167-74. Rev Prat. 2004. PMID: 15496022 Review. French.
-
Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats.Life Sci. 2005 Sep 16;77(18):2233-45. doi: 10.1016/j.lfs.2004.12.048. Life Sci. 2005. PMID: 15963533
-
The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.Fundam Clin Pharmacol. 2009 Dec;23(6):693-703. doi: 10.1111/j.1472-8206.2009.00780.x. Epub 2009 Oct 9. Fundam Clin Pharmacol. 2009. PMID: 19817870 Review.
-
RAS inhibition in hypertension.J Hum Hypertens. 2006 Feb;20(2):101-8. doi: 10.1038/sj.jhh.1001960. J Hum Hypertens. 2006. PMID: 16397519 Review.
-
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.Am J Hypertens. 2008 Mar;21(3):248-56. doi: 10.1038/ajh.2007.56. Epub 2008 Jan 24. Am J Hypertens. 2008. PMID: 18219303 Review.
Cited by
-
miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap.J Biol Chem. 2023 Dec;299(12):105478. doi: 10.1016/j.jbc.2023.105478. Epub 2023 Nov 21. J Biol Chem. 2023. PMID: 37981211 Free PMC article.
-
Cardiac insulin resistance and microRNA modulators.Exp Diabetes Res. 2012;2012:654904. doi: 10.1155/2012/654904. Epub 2011 Jul 31. Exp Diabetes Res. 2012. PMID: 21977024 Free PMC article. Review.
-
Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and improves cell adhesion in trinitrobenzene sulfonic acid-induced colitis in rats.Drug Deliv. 2022 Dec;29(1):2017-2028. doi: 10.1080/10717544.2022.2086939. Drug Deliv. 2022. PMID: 35766160 Free PMC article.
-
Activation of the ACE2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction.Neuroscience. 2014 Jul 25;273:39-51. doi: 10.1016/j.neuroscience.2014.04.060. Epub 2014 May 9. Neuroscience. 2014. PMID: 24814023 Free PMC article.
-
Clarification of hypertension mechanisms provided by the research of central circulatory regulation.Hypertens Res. 2023 Aug;46(8):1908-1916. doi: 10.1038/s41440-023-01335-6. Epub 2023 Jun 5. Hypertens Res. 2023. PMID: 37277436 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical
Miscellaneous